Journal
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY
Volume 20, Issue 5, Pages 941-957Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.bpg.2006.04.004
Keywords
oesophageal cancer; neoadjuvant therapy; therapy response assessment; CT; EUS; FDG-PET
Categories
Ask authors/readers for more resources
Neoadjuvant or adjuvant multimodality therapy in oesophageal cancer is introduced in an effort to improve prognosis. However, in a substantial fraction of patients there is no response to this non-surgical therapy. Non-invasive imaging modalities such as computed tomography (CT), endoscopic ultrasound (EUS) and 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) have been evaluated for assessing patient response to therapy, and these are described in this review. Currently, FDG-PET seems to be the best available tool for neoadjuvant therapy response assessment in oesophageal cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available